1: DiVincenzo C et al. The alle/ic spectrum of Charcot-Marie-Tooth disease in over 17’000 idividua/s with neuropathy. Molecular Genetics & Genomic Medicine. 2014:522-9.

2: Shy ME et al. Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 2008;70:378-83.

3: Bird TD. Charcot-Marie-Tooth Neuropathy Type 1. ln: Pagan RA, Adam MP, Ardinger HH et al. editors. GeneReviews® . Seattle (WA): University of Washington, Seattle; 1993-2015. 1998 Aug 31 [updated 2015 Mar 26].

4: Brennan KM, Bai Y, Shy ME. Demye/inating CMT–what’s known, what’s new and what’s in store? Neurosci Lett. 2015;596:14-26.

5: Saporta AS, Sottile SL, Miller LJ, et al. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neural. 2011 ;69:22-33

6: Grandis M, Shy ME. Current Therapy for Charcot-Marie-Tooth Disease. Curr Treat Options Neural. 2005;7:23-31.

7: Schrôder JM. Neuropathology of Charcot-Marie-Tooth and related disorders. Neuromolecular Med. 2006;8:23-42.

8: Franssen H. Electrophysiology in demyelinating polyneuropathies. Expert Rev Neurother. 2008;8:417-31.

9: Shy ME, Blake J, Krajewski K et al. Reliability and validity of the GMT neuropathy score as a measure of disability. Neuro/ogy. 2005;64: 1209-14.

10: Graham RC, Hughes RA. A modified peripheral neuropathy scale: the Overa/1 Neuropathy Limitations Scale. J Neural Neurosurg Psychiatry. 2006;77:973-6.